


## Data Sheet

|                           |  |
|---------------------------|--|
| <b>Product Name:</b>      | Erteberel                                      |
| <b>Cat. No.:</b>          | CS-0007402                                     |
| <b>CAS No.:</b>           | 533884-09-2                                    |
| <b>Molecular Formula:</b> | C <sub>18</sub> H <sub>18</sub> O <sub>3</sub> |
| <b>Molecular Weight:</b>  | 282.33   |
| <b>Target:</b>            | Estrogen Receptor/ERR                          |
| <b>Pathway:</b>           | Others   |
| <b>Solubility:</b>        | DMSO : ≥ 30 mg/mL (106.26 mM)                  |



### BIOLOGICAL ACTIVITY:

Erteberel (LY500307) is a potent and selective estrogen receptor beta (**ERβ**) agonist with **K<sub>i</sub>** and **EC<sub>50</sub>** of 1.54 nM and 3.61 nM, respectively<sup>[1]</sup>. Anti-tumor activities<sup>[2]</sup>. IC50 & Target: Ki: 1.54 nM (ERβ)<sup>[1]</sup>

EC50: 3.61 nM<sup>[1]</sup>

**In Vitro:** Treatment with Erteberel (0.25-10 μM, 72 hours) significantly reduces the proliferation of GBM cells with no activity on normal astrocytes in vitro<sup>[2]</sup>.

Erteberel promotes apoptosis of GBM cells. Erteberel modulated several pathways related to apoptosis, cell cycle, and DNA damage response<sup>[2]</sup>.

Erteberel (0-1000 μM) sensitizes GBM cells to several FDA-approved chemotherapeutic drugs including cisplatin, lomustine and temozolomide<sup>[2]</sup>.

**In Vivo:** Erteberel (5 mg/Kg body weight/day, oral, 28 days) treatment significantly reduces tumor growth and promotes apoptosis of GBM tumors in an orthotopic model<sup>[2]</sup>.

Erteberel (5 mg/Kg body weight/day, oral, 40-50 days) treatment improves the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model<sup>[2]</sup>.

### References:

[1]. Zhao L, et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3673-E3681.

[2]. Sareddy GR, et al. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep. 2016 Apr 29;6:24185.

### CAIndexNames:

Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aS,4R,9bR)-

### SMILES:

OC1=CC=C2C([C@@](CCC3([H])[C@@]3([H])[C@H](C4=CC=C(O)C=C4)O2)=C1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA